Literature DB >> 6978457

The measurement of leukocyte subsets in the peripheral blood of cancer patients with solid tumors using monoclonal antibody reagents.

J E Harris, K P DeBoer, A L Vahey, D P Braun.   

Abstract

Monocyte and lymphocyte subsets were quantitated in the peripheral blood of normal subjects and patients with solid tumors using the monoclonal antibody reagents OKM1, BRL63D3, OKT3, OKT4, and OKT8. Percentages and numbers of cells reacting with monoclonal reagents were analyzed by indirect immunofluorescence. Correlations between leukocyte subset values and stage of disease or immunocompetence were sought. No differences from normal were seen in the percentage of OKT3, OKT4, and OKT8 cells or in the ratios of OKT4/OKT8 cells in peripheral blood mononuclear cells (PBMC) from all cancer patients, patients with localized disease, or patients with advanced disease. A significant decrease in absolute numbers of lymphocytes, OKT3 cells, OKT4 cells, and OKT8 cells was seen in the peripheral blood of patients with advanced disease reflecting the absolute lymphopenia of these patients. A significant increase was seen in the percentages of PBMC reacting with OKM1 and BRL63D3 from patients with advanced disease compared with normal donors or localized disease patients. A positive correlation was found between PHA responsiveness and absolute numbers of OKT3 and OKT4 cells. A negative correlation was found between PHA responsiveness and percentages of OKM1 cells. These data indicate that malignant disease does not alter T cell subset percentages in patient peripheral blood but may decrease their absolute numbers in association with absolute lymphopenia. On the other hand, percentages of OKM1 and BRL63D3 cells are increased in patients with advanced solid tumors in association with impaired PHA responsiveness.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6978457     DOI: 10.1002/mpo.2950100214

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  3 in total

1.  The relationship between clinical stage, natural killer activity and related immunological parameters in adenocarcinoma of the prostate.

Authors:  N Lahat; B Alexander; D R Levin; B Moskovitz
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

Review 2.  Serial immune function testing to predict clinical disease relapse in patients with solid tumors.

Authors:  D P Braun; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

3.  Characterization of peripheral blood T-cell subpopulation of bladder cancer patients.

Authors:  A Greenstein; M Pecht; I Kaver; N Trainin; Z Braf
Journal:  Urol Res       Date:  1991
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.